Scheinberg / Jurcic Treatment of Leukemia and Lymphoma

1. Auflage 2004
ISBN: 978-0-08-049040-3
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band Volume 51, 384 Seiten, Web PDF

Reihe: Advances in Pharmacology

New Treatments of Leukemia and Lymphoma describes the most important advances in the therapy of hematopoietic cancers that have been derived from recent discoveries in cancer cell biology, kinase biochemistry, and immunology. Detailed descriptions of the large number of new and effective agents that have recently become available for the treatment of leukemias and lymphomas as well as an understanding of their mechanisms of action and their integration into current therapy are provided. A number of experimental drug reagents currently in clinical investigation are also discussed. The therapies include conventional anti-metabolites, monoclonal antibodies directed to cell surface receptors, antibodies tagged with toxins and radiopharmaceuticals, inhibitors of specific kinases, stem cell transplants, and engineered T-cells designed to selectively target hematopoietic cancers. The contents of the book will allow practitioners and investigators alike to understand what is current and state of the art as well as what to look for in the future.* Provides an up-to-date, state of the art discussion of a rapidly changing field * Great breadth covering conventional chemotherapeutic agents, biologic agents such as antibodies, novel small molecule inhibitors and genetically engineered cells * Written by international experts in each of the fields

Autoren/Hrsg.

Scheinberg, David A.

Jurcic, Joseph G.

Inhaltsverzeichnis

1;Cover;1
2;Copyright Page;5
3;Contents;6
4;Contributors;12
5;Preface;16
6;Chapter 1. Kinase Inhibitors in Leukemia;20
6.1;I. Chapter Overview;20
6.2;II. Introduction;21
6.3;III. Factors in Identifying an Ideal Therapeutic Target;21
6.4;IV. Kinase Targets in Leukemia: Current Treatment Options;24
6.5;V. Kinase Targets in Leukemia: On the Horizon;33
6.6;VI. Conclusions;39
6.7;References;39
7;Chapter 2. Therapy of Acute Promyelocytic Leukemia;54
7.1;I. Chapter Overview;54
7.2;II. Introduction;54
7.3;III. Disease Background and Biology;55
7.4;IV. Treatment Approaches;57
7.5;References;71
8;Chapter 3. Investigational Agents in Myeloid Disorders;78
8.1;I. Chapter Overview;78
8.2;II. Introduction;79
8.3;III. Nucleoside Analogs;79
8.4;IV. Reversal of Multidrug Resistance;85
8.5;V. Biological Agents;87
8.6;VI. Signaling Modulators;93
8.7;VII. Conclusions;101
8.8;References;101
9;Chapter 4. Methodologic Issues in Investigation of Targeted Therapies in Acute Myeloid Leukemia;118
9.1;I. Chapter Overview;118
9.2;II. Introduction;118
9.3;III. Patient Selection for Targeted Therapy Trials in Acute Myeloid Leukemia;119
9.4;IV. Endpoints for Clinical Trials of TTs in ANL;121
9.5;V. Need for Randomized Trials of TTs and a Proposed Statistical Design;122
9.6;References;125
10;Chapter 5. Purine Analogs in Leukemia;126
10.1;I. Chapter Overview;126
10.2;II. Introduction;126
10.3;III. Mechanisms of Action;127
10.4;IV. Purine Analogs in Chronic Lymphocytic Leukemia;129
10.5;V. Purine Analogs in Hairy Cell Leukemia;133
10.6;VI. Purine Analogs in Acute Myeloid Leukemia;133
10.7;VII. Purine Analogs in Chronic Myeloid Leukemia;135
10.8;VIII. Purine Analogs in Allogeneic Stem Cell Transplantation;136
10.9;IX. Conclusion and Future Directions;137
10.10;References;137
11;Chapter 6. Monoclonal Antibody Therapy in Lymphoid Leukemias;146
11.1;I. Chapter Overview;146
11.2;II. Introduction ;147
11.3;III. Chronic Lymphocytic Leukemia;149
11.4;IV. T-Cell Prolymphocytic Leukemia;171
11.5;V. Hairy Cell Leukemia;172
11.6;VI. Conclusions;174
11.7;References;175
12;Chapter 7. Native Antibody and Antibody-Targeted Chemotherapy for Acute Myeloid Leukemia;188
12.1;I. Chapter Overview;188
12.2;II. Introduction;189
12.3;III. Lingering Questions Regarding Immunoconjugate Therapies;197
12.4;IV. Summary;199
12.5;References;200
13;Chapter 8. Radioimmunotherapy of Leukemia;204
13.1;I. Chapter Overview;204
13.2;II. Introduction;205
13.3;III. Antigenic Targets;205
13.4;IV. Radioisotope Selection;206
13.5;V. Radiolabeling;209
13.6;VI. Pharmacokinetics and Dosimetry;212
13.7;VII. Radioimmunotherapy with b-Particle Emitters;213
13.8;VIII. Radioimmunotherapy with a-Particle Emitters;218
13.9;IX. Summary;221
13.10;References;222
14;Chapter 9. Immunotoxins and Toxin Constructs in the Treatment of Leukemia and Lymphoma;228
14.1;I. Chapter Overview;228
14.2;II. Introduction;228
14.3;III.‘‘Targets of Opportunity’’ in Leukemia and Lymphoma;229
14.4;References;240
15;Chapter 10. Antibody Therapy of Lymphoma;248
15.1;I. Chapter Overview;248
15.2;II. History;249
15.3;III. Chimeric Anti-CD20„A Clinical Breakthrough;251
15.4;IV. Alternative Molecular Targets;253
15.5;V. Mechanisms of Action;255
15.6;VI. Radioimmunotherapy;260
15.7;VII. mAbs Combined with Chemotherapy;262
15.8;VIII. mAbs Combined with Immunotherapy;265
15.9;IX. Conclusion;266
15.10;References;267
16;Chapter 11. Vaccines in Leukemia;274
16.1;I. Chapter Overview;274
16.2;II. Introduction;275
16.3;III. Potential Target Antigens ;276
16.4;IV. Clinical Vaccine Trials with Leukemia-Associated Antigens;281
16.5;V. Conclusion;283
16.6;References;283
17;Chapter 12. Therapeutic Idiotype Vaccines for Non-Hodgkin’s Lymphoma;290
17.1;I. Chapter Overview;290
17.2;II. Introduction;291
17.3;III. Development of the Idiotype Vaccine Approach;291
17.4;IV. Recombinant Idiotype Vaccines;297
17.5;V. Phase III Idiotype Vaccine Trials;301
17.6;VI. Pharmacologic Considerations and Integration with Standard Therapies;302
17.7;VII. New and Ongoing Phase I/II Clinical Trials of Idiotype Vaccination;304
17.8;VIII. Conclusions and Future Prospects;306
17.9;References;307
18;Chapter 13. Cytokine Modulation of the Innate Immune System in the Treatment of Leukemia and Lymphoma;314
18.1;I. Chapter Overview;314
18.2;II. Introduction;315
18.3;III. Effector Cells of the Innate Immune System: Relevance to Cytokine Therapy;315
18.4;IV. Cytokine Therapy: Exploiting Innate Immune Effectors;321
18.5;V. Novel Approaches for the Immunomodulation of Leukemia and Lymphoma;325
18.6;VI. Conclusion;330
18.7;References;330
19;Chapter 14. Donor Lymphocyte Infusions;338
19.1;I. Chapter Overview;338
19.2;II. Introduction;338
19.3;III. Graft-Versus-Leukemia: Experimental Models;339
19.4;IV. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia;340
19.5;V. Multiple Myeloma;343
19.6;VI. Myelodysplastic Syndrome and Acute Leukemia;345
19.7;VII. Chronic Lymphocytic Leukemia and Lymphoma;346
19.8;VIII. EBV-Associated Lymphoproliferative Disorders After Bone Marrow Transplantation;346
19.9;IX. Complications of DLI;347
19.10;X. Methods to Enhance the GVL Response after DLI;349
19.11;XI. Mediators of the GVL Effect;349
19.12;XII. Potential Targets of the GVL Effect;351
19.13;XIII. Tumor-Specific Targets of the DLI/GVL Response;354
19.14;XIV. Future Directions;355
19.15;References;356
20;Chapter 15. Somatic Cell Engineering and the Immunotherapy of Leukemias and Lymphomas;366
20.1;I. Chapter Overview;366
20.2;II. Introduction;367
20.3;III. Immune Effector Cell Activation;369
20.4;IV. Immunization Against Hematologic Malignancies: Tumor Cell Vaccines;370
20.5;V. Immunization Against Hematologic Malignancies: Dendritic Cell Vaccines;376
20.6;VI. Adoptive T-Cell Therapy Directed Against Hematologic Malignancies;378
20.7;VII. Conclusion;381
20.8;References;382
21;Index;390
22;Contents of Previous Volumes;402
23;Color Plate Section;413